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Li, Rulin, Martha Chase, Sung-Kwon Jung, Peter J. S.
Smith, and Mary R. Loeken. Hypoxic stress in diabetic preg-
nancy contributes to impaired embryo gene expression and defec-
tive development by inducing oxidative stress. Am J Physiol Endo-
crinol Metab 289: E591–E599, 2005. First published May 31, 2005;
doi:10.1152/ajpendo.00441.2004.—We have shown that neural tube
defects (NTD) in a mouse model of diabetic embryopathy are asso-
ciated with deficient expression of Pax3, a gene required for neural
tube closure. Hyperglycemia-induced oxidative stress is responsible.
Before organogenesis, the avascular embryo is physiologically hy-
poxic (2–5% O2). Here we hypothesized that, because O2 delivery is
limited at this stage of development, excess glucose metabolism could
accelerate the rate of O2 consumption, thereby exacerbating the
hypoxic state. Because hypoxia can increase mitochondrial superox-
ide production, excessive hypoxia may contribute to oxidative stress.
To test this, we assayed O2 flux, an indicator of O2 availability, in
embryos of glucose-injected hyperglycemic or saline-injected mice.
O2 flux was reduced by 30% in embryos of hyperglycemic mice. To
test whether hypoxia replicates, and hyperoxia suppresses, the effects
of maternal hyperglycemia, pregnant mice were housed in controlled
O2 chambers on embryonic day 7.5. Housing pregnant mice in 12%
O2, or induction of maternal hyperglycemia (250 mg/dl), decreased
Pax3 expression fivefold, and increased NTD eightfold. Conversely,
housing pregnant diabetic mice in 30% O2 significantly suppressed
the effect of maternal diabetes to increase NTD. These effects of
hypoxia appear to be the result of increased production of mitochon-
drial superoxide, as indicated by assay of lipid peroxidation, reduced
glutathione, and H2O2. Further support of this interpretation was the
effect of antioxidants, which blocked the effects of maternal hypoxia,
as well as hyperglycemia, on Pax3 expression and NTD. These
observations suggest that maternal hyperglycemia depletes O2 in the
embryo and that this contributes to oxidative stress and the adverse
effects of maternal hyperglycemia on embryo development.
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DIABETIC EMBRYOPATHY IS A COMPLICATION of diabetes in which
the embryo of a diabetic mother develops congenital malfor-
mations. Diabetic pregnancy-induced malformations arise at
the earliest stages of organogenesis, corresponding to approx-
imately the first 8 wk of human gestation (36). Virtually any
organ system is subject to malformation, but the neural tube
and the heart are most commonly affected (4, 37). Offspring of
women with either type 1 or type 2 diabetes are at risk for
diabetic embryopathy (51), suggesting that hyperglycemia, and
consequent increased glucose transport to the embryo, is re-
sponsible.
To understand the biochemical and molecular mechanisms
by which maternal hyperglycemia leads to congenital malfor-
mations, we have employed a mouse model of diabetic preg-
nancy that leads to a significant increase in neural tube defects
(NTD; see Ref. 41). We have shown that maternal diabetes
induced by streptozotocin (STZ), or transient induction of
hyperglycemia (13.9 mM) by glucose injection on embryonic
day 7.5 leads to decreased expression of Pax3 beginning on
day 8.5 and increased incidence of NTD, which can be recog-
nized by day 10.5 (20, 41). Pax3 encodes a transcription factor
that is expressed in neuroepithelium, neural crest, and somitic
mesoderm (24). Homozygous Splotch embryos (Sp/Sp) carry
loss of functional Pax3 alleles and develop defects of the
neural tube (exencephaly, spina bifida, or both), neural crest,
and skeletal muscle with 100% penetrance (3, 7, 17, 23). They
die by day 16.5 of gestation, resulting from defective migration
of neural crest cells to the heart (13). Heterozygous Sp/ mice
are viable, although they are recognizable by white patches of
fur resulting from maldevelopment of neural crest-derived
melanocytes. Because the exencephaly affecting embryos of
diabetic mice and Sp/Sp embryos are morphologically quite
similar, this suggests that deficient expression of Pax3 pheno-
copies Pax3 loss-of-function mutations. Undoubtedly, there are
other genes in which expression could be inhibited by maternal
diabetes and lead to defects of other organs or contribute to
NTD. However, because Pax3 is an absolutely essential gene
for development, if its expression alone is reduced below a
critical threshold, an NTD will occur. Therefore, investigating
how Pax3 is regulated by maternal diabetes is itself important,
and may serve as a general model of how embryo gene
expression is disturbed during diabetic pregnancy.
Many studies using rodent embryos have shown that reactive
oxygen species are increased by maternal diabetes or high-
glucose culture and that administration of antioxidants, or
transgenic overexpression of Cu2/Zn2 superoxide dis-
mutase, can prevent hyperglycemia-induced developmental de-
fects (12, 18, 19, 25, 42, 46, 47, 54). We showed that oxidative
stress, caused by maternal diabetes or administration of anti-
mycin A (AA), a mitochondrial complex III inhibitor that
increases superoxide production (52), inhibits Pax3 expression
and increases NTD (12). Increased oxidant status is likely to be
complex, involving a combination of increased superoxide
production as well as impaired free radical scavenging, and the
pathways responsible for increased oxidant status have not
been completely elucidated.
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The stage of early postimplantation development that is
vulnerable for induction of NTD is just before the development
of the circulatory system and coincides with a stage of devel-
opment in which the embryo is relatively hypoxic (2–8% O2,
compared with 20% in maternal arterial circulation; see Refs.
21 and 44). Indeed, delivery of O2 is diffusion limited, and the
increasing mass of the embryo causes a state of physiological
hypoxia that activates genes that induce formation of the
circulatory system (1). Thus a slight increase in oxidative
glucose metabolism resulting from increased glucose delivery
to the embryo may accelerate O2 utilization before establish-
ment of the circulatory system can augment O2 delivery. This
could lead to a state of hypoxia in excess of the physiological
hypoxia that is part of normal development. Hypoxia can
stimulate mitochondrial production of O2 at complexes II and
III (9–11, 38, 43). Thus it is possible that oxidative stress in the
embryo might be the result of, at least in part, hypoxia-
dependent superoxide production, as a consequence of O2
depletion from increased glucose oxidation.
In this study, we tested the hypothesis that maternal hyper-
glycemia increases the hypoxic state of the embryo, leading to
inhibited Pax3 expression and increased NTD, and whether
this was associated with increased oxidative stress.
MATERIALS AND METHODS
Induction of diabetes and transient hyperglycemia. A flow chart of
animal procedures is shown in Fig. 1. Diabetes was induced in 5- to
6-wk-old female ICR mice (Taconic, Germantown, NY), as described
previously (41), with 100 mg/kg STZ (Sigma, St. Louis, MO) dis-
solved in 10 mM sodium citrate (pH 4.5) and treated with subcuta-
neously implanted insulin pellets (Linshin, Scarborough, Ontario).
Blood glucose was monitored daily with a Glucometer Elite (Bayer,
Mishawaka, IN). STZ-diabetic mice maintained euglycemia with
insulin pellets before pregnancy but developed hyperglycemia begin-
ning on day 4.5 of pregnancy, thereby exposing the embryo to
hyperglycemia during the entire postimplantation period. Transient
hyperglycemia was induced by subcutaneous injection of 12.5%
glucose dissolved in PBS at approximately hourly intervals to main-
tain blood glucose 16.7 mmol/l, as described previously (20).
Controls were injected in parallel with PBS. Oxidative stress was
induced on day 7.5 with AA (Sigma Chemicals) dissolved in 25%
(vol/vol) propylene glycol and administered at 3 mg/kg body wt at
noon on day 7.5, as described previously (12). Glutathione (GSH)
ethyl ester (EE; Sigma Chemicals) dissolved in PBS was administered
at 1 mmol/kg, in three doses on day 7.5 as described (28). Vitamin
E-treated animals received chow supplemented with 0.125% (wt/wt)
()--tocopherol succinate, which increased dietary intake of vitamin
E by 21-fold, beginning on day 0.5 of pregnancy as described (12).
Mice were killed to recover embryos for assay of markers of oxidative
stress on day 7.5, for assay of Pax3 expression on day 8.5, or to score
NTD on day 10.5. All procedures performed using animals that are
described herein were approved by the Institutional Animal Care and
Use Committees of the Joslin Diabetes Center and the Marine Bio-
logical Laboratory.
Recording embryo O2 flux. Preparation of O2 microsensors and O2
flux measurement were performed as described previously (31, 33, 48,
49) and as diagramed in Fig. 2A. Briefly, the microsensor, fabricated
from platinum wire inserted in a pulled glass capillary, was placed
adjacent to the target tissue and then oscillated with a frequency of 0.3
Hz over a distance of 10 m. One-third of the data, collected during
the movement of the probe and during the period of settlement after
the movement, was discarded automatically. Comparison of the cur-
rent from the near pole and far pole allows a differential measurement
directly proportional to flux while simultaneously removing the back-
ground signal.
Experiments were conducted in a Faraday box mounted on an air
table, incorporating a Zeiss Axioskop upright microscope. Tempera-
ture was held at 37°C. The motion controllers, temperature controller
and amplifiers, as well as coordinating software (IonView) were
products of the BioCurrents Research Center (Marine Biological
Laboratory, Woods Hole, MA; www.mbl.edu/BioCurrents).
For recording O2 flux in embryos on day 7.5 of pregnancy,
nondiabetic mice were injected with 12.5% glucose to induce hyper-
glycemia as described above and in Ref. 20. After 3 h of hypergly-
cemia, mice were killed, and decidua were immediately removed from
uteri and dissected in 37°C PBS to expose yolk sac-enclosed embryos.
The yolk sac was pierced over the head fold, and O2 flux was recorded
adjacent to the cranial neuroepithelium (Fig. 2B). Oxygen tension in
the medium was atmospheric, giving rise to a concentration of
210 M.
Fig. 1. Flow diagram of animal procedures as described in MATERIALS AND METHODS. For animals to be made diabetic, diabetes was induced with streptozotocin
(STZ) about 3 wk before mating. Nondiabetic mice were either controls for the diabetic mice or were used for manipulation of glycemia, oxygenation, and/or
oxidant status in the absence of diabetes. Mice were mated along with age-matched controls, and noon of the day on which a copulation plug was found was
determined to be day (d) 0.5. Mice were maintained on control breeder chow, except for mice in which the effects of vitamin E were tested, which were given
chow supplemented with 0.125% vitamin E succinate. On day 7.5, hyperglycemia was induced in some nondiabetic mice by subcutaneous glucose administration
(controls were injected with saline); hypoxia was induced in nondiabetic mice by housing in a 12% O2 chamber; hyperoxia was induced in diabetic and
nondiabetic mice by housing in a 30% O2 chamber; oxidative stress was induced in nondiabetic mice by administration of antimycin A; and the antioxidant
glutathione (GSH) ethyl ester was administered to hyperglycemic, hypoxic, or saline-injected mice. Pregnant mice were killed for recovery of embryos at 1 of
the following 3 time points: on day 7.5 after 3 h of hyperglycemia, hypoxia, or oxidative stress to assay O2 flux or markers of oxidative stress; on day 8.5 to
assay Pax3 mRNA; or on day 10.5 to score neural tube defects (NTD).
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Hypoxic and hyperoxic exposure. For induction of hypoxia and
hyperoxia, pregnant mice were housed on day 7.5 in an OxyCycler
chamber from Reming Bioinstruments (Redfield, NY), which is a
semi-sealed, four-chamber Plexiglas incubator containing an O2 sen-
sor and a small, quiet fan inside to provide forced circulation and
instant homogenization of gases. It is attached to a computer for
programmable adjustment of chamber O2 concentrations. To induce
hypoxia, the chamber O2 concentration is reduced to 12% in 2%
increments over a 15-min period. To induce hyperoxia, the chamber
O2 concentration was increased to 30% within a 5-min period. Mice
were exposed to hypoxia or hyperoxia for 3 h for experiments
assaying markers of oxidative stress and 8 h for experiments assaying
Pax3 mRNA or NTD.
Assay of malondialdehyde, GSH, and H2O2. Embryos, including
extraembryonic membranes, were recovered on day 7.5, and one-third
of the embryos from each pregnancy was pooled and saved for assay
of malondialdehyde (MDA), GSH, or H2O2. MDA was assayed
spectrophotometrically, as described previously (15), using purified
MDA (Sigma Chemicals) to generate a standard curve. GSH and
H2O2 were assayed using kits obtained from Cayman Chemicals (Ann
Arbor, MI) according to the manufacturer’s instructions. The GSH kit
measures total GSH and oxidized GSH (GSSG); GSH was determined
from the difference between total GSH and GSSG. MDA, GSH, and
H2O2 were normalized to protein concentrations in cell extracts,
which were assayed using the Bio-Rad protein reagent (Bio-Rad,
Hercules, CA).
Assay of Pax3 expression. Embryos from individual pregnancies
were pooled, and RNA was prepared as described (40). Pax3 mRNA
in each pregnancy was quantitated relative to one arbitrarily selected
saline or nondiabetic/20% O2 pregnancy, after normalization to
rRNA, using real-time RT-PCR, as described previously (12).
Statistical analyses. Data were analyzed from a minimum of three
pregnancies per treatment group by one-way ANOVA, followed by
the Neuman-Keuls post hoc test, using GraphPad Prism software (San
Diego, CA).
RESULTS
Maternal hyperglycemia suppresses aerobic respiration.
Aerobic respiration depends on O2 delivery. Thus, although
glucose metabolism in the day 7.5 mouse embryo is predom-
inantly anaerobic (2), we hypothesized that an increase in
glucose delivery to the embryo resulting from maternal hyper-
glycemia would transiently increase aerobic metabolism. Thus,
if O2 were consumed faster than it can be replenished, this
would suppress aerobic metabolism by the embryo, leading to
decreased O2 flux. To test this, we assayed O2 flux, which is an
indicator of aerobic metabolism, in day 7.5 embryos after 3 h
of maternal hyperglycemia (16.7 mmol/l) using self-refer-
encing O2 microelectrodes (Fig. 2A). An image of a microelec-
trode next to a yolk sac-enclosed embryo is shown in Fig. 2B.
As shown in Fig. 2C, O2 flux was reduced significantly in
embryos of hyperglycemic mice. This indicates that, consistent
with the hypothesis, after 3 h of maternal hyperglycemia,
aerobic respiration was suppressed, suggesting that a state of
hypoxia in excess of that of normal day 7.5 embryos was
induced.
Maternal hypoxia replicates, and hyperoxia suppresses, the
effects of maternal diabetes on Pax3 expression and NTD. If
hyperglycemia inhibits Pax3 expression and increases NTD by
inducing hypoxic stress in the embryo, then reducing O2
delivery to embryos should replicate the effects of maternal
hyperglycemia, and increasing O2 delivery should block the
effects of maternal diabetes.
To test whether reducing O2 delivery to embryos replicates
the adverse effects of hyperglycemia, pregnant mice were
housed in a programmable O2 chamber, ramping down from
room air (20% O2) to 12% O2 on day 7.5. Mice were made
hyperglycemic by glucose injection or injected with saline as
Fig. 2. A: diagram of O2 flux recording. The computer [personal computer (PC) with IonView software] serves the following 2 functions: to control electrode
movement and to record O2 flux. Electrode movement is directed to cause the head stage to move the microelectrode back and forth within 10 m of the target
tissue at a frequency of 0.3 Hz. The current generated by the O2 gradient at the near pole (adjacent to the target tissue) and the far pole (10 m from the target
tissue) is transmitted through the main amplifier to the computer. B: image of day 7.5 yolk sac-enclosed embryo next to microelectrode used to record O2 flux.
C: O2 flux assayed in embryos of saline- or glucose-injected mice. *P  0.005; n, no. of embryos assayed.
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controls. Table 1 shows that there was no effect of maternal
hypoxia on blood glucose concentrations, whereas glucose
injection significantly increased maternal blood glucose con-
centrations. Nevertheless, maternal hypoxia, like maternal hy-
perglycemia, significantly inhibited Pax3 expression and in-
creased NTD (Fig. 3, A and B).
To test whether increasing O2 delivery blocks the adverse
effects of maternal diabetes, diabetic or nondiabetic mice were
housed at 30% O2 on day 7.5 of pregnancy. Control diabetic
and nondiabetic mice were kept in room air (20% O2). As
shown in Table 2, hyperoxia had no effect on maternal blood
glucose concentrations, which were significantly elevated in
diabetic mice. Nevertheless, although hyperoxia had no effect
on Pax3 expression and NTD in embryos of nondiabetic mice,
it blocked the inhibition of Pax3 expression and NTD in
embryos of diabetic mice (Fig. 3, C and D).
Hypoxic stress induces oxidative stress in embryos. We have
previously shown that oxidative stress, induced by maternal
hyperglycemia or the mitochondrial complex III inhibitor, AA,
inhibits Pax3 expression and induces NTD (12). Noting that
hypoxic stress can stimulate superoxide production (9–11, 38,
43), we hypothesized that the adverse effects of hyperglyce-
mia-induced hypoxic stress on Pax3 expression and NTD
could be mediated, at least in part, by oxidative stress. To test
this hypothesis, we assayed markers of oxidative stress (MDA
and GSH, as well as H2O2, the production of which is in-
creased upon increased superoxide production) after 3 h of
maternal exposure to 12% O2. As shown in Fig. 4A, MDA, a
marker of lipid peroxidation, was significantly increased by
maternal hypoxia to the same extent that it was increased by
hyperglycemia or AA. Another indicator of oxidative stress,
GSH, was significantly decreased by hypoxia to the same
extent that it was decreased by hyperglycemia or AA (Fig. 4B).
H2O2 was increased equally by hypoxia, hyperglycemia, and
AA (Fig. 4C).
Conversely, we tested whether increasing O2 delivery to
embryos blocks oxidative stress induced by maternal diabetes.
There was no effect of hyperoxia (30% O2) on MDA in
nondiabetic pregnancies, but the increase in MDA observed in
diabetic pregnancies was significantly reduced by hyperoxia,
although it was still significantly increased over MDA in
nondiabetic pregnancies exposed to either normoxia or hyper-
oxia (Fig.4D). Similarly, there was no effect of hyperoxia on
GSH, but the decrease in GSH induced by maternal diabetes
was significantly reduced by hyperoxia, although GSH was
still significantly reduced in embryos of diabetic mice exposed
to hyperoxia compared with embryos of nondiabetic mice
exposed to either normoxia or hyperoxia (Fig. 4E). The in-
crease in H2O2 observed in diabetic pregnancies was signifi-
cantly suppressed by hyperoxia, although it remained signifi-
cantly increased compared with nondiabetic pregnancies ex-
posed to either normoxia or hyperoxia (Fig. 4F).
Antioxidant administration blocks the adverse effects of
embryo hypoxia on neural tube development. To further test
the hypothesis that hypoxic stress induces oxidative stress,
Table 1. Mean blood glucose levels of pregnancies
in Fig. 3, A and B
Saline Glucose Hypoxia
Day 7.5 blood glucose, mM 7.00.08 19.30.46* 7.10.13
Values are means  SE. *P  0.001 vs. saline and hypoxia.
Fig. 3. Effects of hypoxia or hyperoxia on Pax3 expres-
sion and NTD. A and B: pregnant mice were housed at
12% O2 on day 7.5 of pregnancy or injected with
glucose to induce hyperglycemia or saline as a control,
as described in MATERIALS AND METHODS. C and D:
pregnant diabetic (D) or nondiabetic (ND) mice were
housed in room air (20% O2, normoxia) or at 30% O2
on day 7.5, as described in MATERIALS AND METHODS.
Embryos were recovered on day 8.5 to assay relative
Pax3 expression by RT-PCR (A and C), or on day 10.5
to score NTD (B and D). A: *P  0.01 vs. saline. B:
*P  0.0005 vs. saline. C: *P  0.001 vs. all other
treatment groups. D: *P  0.01 vs. all other treatment
groups; n, no. of pregnancies assayed.
Table 2. Mean blood glucose levels of pregnancies
in Fig. 3, C and D
ND/Normoxia ND/Hyperoxia D/Normoxia D/Hyperoxia
Day 7.5 blood
glucose, mM 7.20.084 7.10.131 30.10.833* 29.61.060*
Values are means  SE. ND, nondiabetic; D, diabetic. *P  0.001 vs. ND.
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which thereby mediates the adverse effects of maternal hyper-
glycemia, the membrane-soluble GSH analog GSH-EE was
administered on day 7.5 to mice that were housed at 12% O2,
or to glucose- or saline-injected mice as controls. Noting that
opening chamber door had the potential to restore normoxia
during the three times that GSH-EE was administered to
animals housed in the O2 chamber, the effect of opening the
door without GSH-EE administration was also tested as a
control.
As shown in Table 3, only glucose-injected mice were
hyperglycemic, and GSH-EE had no effect on glycemia in any
treatment group. In contrast, the inhibition of Pax3 expression
induced by hypoxia or hyperglycemia was prevented by coin-
cident administration of GSH-EE (Fig. 5A). This effect could
not be attributed to transient normoxia during the time the
OxyCycler chamber doors were opened to administer GSH-
EE, since Pax3 expression was still reduced in embryos of
mice exposed to hypoxia during day 7.5 when the chamber
doors were opened for times comparable for injection of
GSH-EE. Correspondingly, the increase in NTD induced by
hypoxia or hyperglycemia was prevented by GSH-EE, and this
cannot be explained by transient normoxia during administra-
tion of GSH-EE (Fig. 5B).
To further test whether the adverse effects of hyperglyce-
mia-induced hypoxia are the result of oxidative stress, the
effects of another antioxidant were tested. Vitamin E succinate,
which we previously showed prevented the adverse effects of
maternal diabetes on Pax3 expression and NTD (12), was
administered by dietary supplementation beginning on day 0.5
of pregnancy. As shown in Fig. 5, C and D, supplemental
vitamin E prevented the inhibition in Pax3 expression and the
increase in NTD induced by hypoxia and hyperglycemia
but had no effect on glycemia (Table 4).
DISCUSSION
There is much evidence implicating oxidative stress in the
pathogenesis of diabetic embryopathy (12, 18, 19, 25, 42, 46,
47, 54). More recently, we have shown that oxidative stress
causes diabetic pregnancy-induced NTD because it disrupts
expression of at least one gene (Pax3), which is crucial for
neural tube development (12). However, the possibility that
maternal hyperglycemia could cause excessive hypoxia in the
embryo, and that this could be a source of oxidative stress, has
not been reported previously.
Fig. 4. Malondialdehyde (MDA), reduced GSH, and H2O2 in pregnancies treated as in Fig. 3. Antimycin A (AA) was administered as a control for stimulation
of H2O2 production. A: *P  0.001 vs. saline. B: *P  0.001 vs. saline; **P  0.001 vs. saline, glucose, and hypoxia. C: *P  0.001 vs. saline. D: *P  0.001
vs. ND (normoxia and hyperoxia); ** P  0.001 vs. all other treatment groups. E: *P  0.001 vs. ND (normoxia and hyperoxia); **P  0.001 vs. all other
treatment groups. F: *P  0.001 vs. ND (normoxia and hyperoxia); **P  0.001 vs. all other treatment groups.
Table 3. Mean blood glucose levels of pregnancies in Fig. 5, A and B
Saline Glucose Hypoxia Saline  GSH Glucose  GSH Hypoxia  GSH Hypoxia  Open Door
Day 7.5 blood glucose, mM 7.40.09 18.60.35* 7.60.17 7.60.12 18.40.28* 7.10.11 7.50.17
Values are means  SE. GSH, glutathione. *P  0.001 vs. all saline and hypoxia groups.
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Physiological hypoxia, caused by the increasing mass of the
avascular early postimplantation embryo, plays a critical role
during normal embryogenesis. As the embryo, which is already
located in a relatively hypoxic environment (21, 44), increases
in mass, O2 delivery becomes increasingly diffusion limited.
This physiological hypoxia activates the Hif-1/ARNT het-
erodimeric transcription factor to induce expression of genes
that trigger formation of blood islands in the yolk sac (1, 22,
30). The primitive circulatory system of the embryo proper is
also dependent on hypoxia-responsive transcription, since em-
bryos lacking EPAS-1, which is hypoxia inducible, fail to
develop a normal heart and circulatory system (50). Thus, in
response to normal growth of the embryo, diffusion-limited O2
delivery induces physiological hypoxia, and this activates ex-
pression of genes whose products induce hematopoiesis and
structures forming the circulatory system, thereby increasing
O2 delivery to embryonic tissues and reducing the hypoxic
state.
Increased O2 delivery may be critical for the development of
organ systems in which primordia appear just after this hy-
poxia-responsive period, such as the neural tube, because
embryos that lack Hif-1, ARNT, VEGF, or sufficient gene
copy numbers of p300 and/or CBP, which encode coactivators
of Hif-1/ARNT-dependent transcription, develop NTD (6,
32, 34, 50, 57). Thus failure to increase O2 delivery at this
stage of development may impair activation of genes needed
for formation of the neural tube. Conversely, increased O2
delivery may be a developmental signal of metabolic fitness to
support further development, which induces expression of
certain genes that control critical developmental programs.
In the rat embryo, only 1.2% of glucose is metabolized
oxidatively on day 10 (corresponding to approximately day 8
in the mouse), but it increases to 8.3% on day 11 (2). The
increase in aerobic metabolism is made possible by increased
O2 delivery from establishment of the primitive yolk sac
circulation. This period of development coincides with the
stage of development that is sensitive to maternal hyperglyce-
mia (20). As shown here, 3 h of maternal hyperglycemia on
day 7.5 decreases O2 flux. This suggests that increased glucose
metabolism, which acutely increases O2 consumption, leads to
relative O2 depletion, thereby inhibiting oxidative metabolism
and suppressing O2 flux. It is also possible that decreased O2
flux could be the result of mitochondrial damage. Indeed, it has
been suggested that exposure of rat embryo or fetal neural
tissues to 50 mM glucose or maternal diabetes can suppress
oxidative metabolism, perhaps because of the Crabtree effect,
in which increased glucose metabolism leads to diminished
supply of ADP, which, by inducing state 4 respiration, in-
creases the production of superoxide (8, 14, 56). Another
possibility is that hyperglycemia-induced increased ratio of
NADH to NAD could cause a “pseudohypoxic” state, despite
normal O2 tension, which has been postulated to be associated
Fig. 5. Effects of GSH ethyl ester (EE) or vitamin (vit)
E succinate on Pax3 expression or NTD induced by
maternal hypoxia. Pregnant mice were housed at 12%
O2 or made hyperglycemic by glucose injection on day
7.5 as in Fig. 3, A and B. Controls were injected with
saline. GSH-EE was administered 3 times during day
7.5 (A and B), or pregnant dams were fed control chow
or chow supplemented with vitamin E succinate from
day 0.5 (C and D). As a control for transient normoxia
while administering GSH to animals housed at 12% O2,
the OxyCycler chamber door was left open for some
hypoxia-exposed dams for the same duration as re-
quired to administer GSH (Hypoxia  open door). A:
*P  0.001 vs. saline, saline  GSH, glucose  GSH,
or hypoxia  GSH. B: *P  0.001 vs. saline, saline 
GSH, glucose  GSH, or hypoxia  GSH. C: *P 
0.001 vs. saline and saline  vit E, P  0.01 vs.
glucose  vit E; **P  0.001 vs. saline and saline 
vit E, P  0.01 vs. hypoxia  vit E. D: *P  0.001 vs.
saline, saline  vit E, glucose  vit E, and hypoxia 
vit E.
Table 4. Mean blood glucose levels of pregnancies in Fig. 5, C and D
Saline Glucose Hypoxia Saline  Vit E Glucose  Vit E Hypoxia  Vit E
Day 7.5 blood glucose, mM 7.20.07 18.90.4* 7.10.13 7.30.05 19.80.26* 7.40.19
Values are means  SE. Vit, vitamin. *P  0.001 vs. all saline and hypoxia groups.
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with diabetic vascular complications (55). Although our results
are not inconsistent with either a Crabtree or pseudo-hypoxic
effect, the fact that the adverse effects of maternal diabetes
could be prevented by transient hyperoxia would suggest that
they are not the result of irreversible mitochondrial damage and
that limiting availability of O2 mediates some of the adverse
effects of maternal hyperglycemia. Thus our findings suggest
that excess glucose stimulates mitochondrial O2 utilization,
leading to a state of hypoxia in excess of that of the normal day
7.5 embryo.
The data reported here support the hypothesis that hypergly-
cemia-induced O2 depletion contributes to the adverse effects
of maternal diabetes on the embryo. Specifically, when O2
depletion was experimentally induced by restricting O2 deliv-
ery to pregnant mice on day 7.5, all of the responses induced
by maternal hyperglycemia (decreased Pax3 expression, in-
creased NTD and markers of oxidative stress) were observed.
Conversely, when increased O2 consumption induced by ma-
ternal diabetes was experimentally compensated by increasing
O2 delivery to pregnant diabetic mice on day 7.5, all of the
responses of maternal diabetes were diminished. This suggests
that excessive embryo hypoxia caused by increased glucose
metabolism suppresses the increase in O2 availability that
would normally occur at this stage of development. Conse-
quently, the processes leading to induction of Pax3, which may
depend on increased O2 delivery, are impaired. A further
implication of these findings is that if, during normal develop-
ment, induction of the blood or circulatory systems in response
to physiological hypoxia fails, for example, because of defi-
cient activation of Hif-1- or Epas-1-dependent transcription,
oxidative stress, leading to insufficient expression of Pax3,
would result. This could explain the NTD that arise in such
animal models.
In considering mechanisms by which glucose-induced ex-
cess hypoxic stress might inhibit Pax3 expression and increase
NTD, we considered several mechanisms, including activation
of Hif-1a-dependent transcription (39, 45) or stimulation of
AMP kinase activity (27, 35). These pathways notwithstand-
ing, noting that hyperglycemia-induced oxidative stress inhib-
its Pax3 expression (12) and that hypoxia has the potential to
increase superoxide production (9–11, 38, 43), we tested
whether oxidant status was increased by hypoxia. Remarkably,
all measures of oxidative stress (MDA, GSH, and H2O2) were
equally affected by hypoxia and by hyperglycemia, and these
markers of oxidative stress were equivalently attenuated by
hyperoxia in embryos of diabetic mice.
Additional evidence that the adverse effects of glucose-
induced hypoxic stress are mediated by oxidative stress was
that the adverse effects of hypoxia were prevented by GSH-EE.
Because GSH could have effects independent of its antioxidant
properties, we tested another antioxidant, vitamin E, which we
previously showed to inhibit the adverse effects of maternal
diabetes on Pax3 expression and NTD (12). Like GSH-EE,
vitamin E also prevented the decrease in Pax3 expression and
Fig. 6. Flow diagram of pathways affected by excess glucose in the embryo leading to impaired Pax3 expression. During diabetic pregnancy, increased glucose
transport from maternal circulation increases glucose metabolism by the embryo. Increased oxidative metabolism increases O2 consumption; however, because
O2 cannot be replaced as quickly as it is consumed, this will lead to decreased O2 availability. Excessive hypoxia increases superoxide and H2O2 production,
thereby increasing reactive oxygen species (ROS), which inhibit Pax3 expression by a yet unidentified mechanism. The effects of oxidative stress can be blocked
by GSH precursors and vitamin E. Other studies have shown that oxidative stress inhibits GAPDH activity and that accumulation of glycolytic intermediates
stimulate the diacylglycerol (DAG)/protein kinase C (PKC) and hexosamine flux pathways. Activation of PKC activity can stimulate NADPH oxidase activity,
leading to decreased production of reduced GSH (although whether PKC regulates Pax3 expression is not known). Activation of the hexosamine flux pathway
inhibits the pentose shunt pathway, thereby decreasing NADPH and reduced GSH production. P, phosphate; G6PD, glucose-6-phosphate dehydrogenase; DH,
dihydroxy; P2, biphospho.
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the increase in NTD induced by hypoxia or by hyperglycemia,
suggesting that the adverse effects of hyperglycemia, leading
to hypoxic stress, are mediated by superoxide-generated oxi-
dative stress.
It is interesting to note that hyperoxia did not increase
markers of oxidant status or inhibit Pax3 expression in nondi-
abetic pregnancies. This suggests that, at this stage of devel-
opment, maternal exposure to 30% O2 does not increase
superoxide production if glucose delivery to the embryo does
not also increase. In diabetic pregnancies, markers of oxidative
stress were significantly improved by hyperoxia. Even though
oxidant status was not completely normalized in diabetic preg-
nancies by hyperoxia, it was apparently corrected sufficiently
to prevent inhibition of Pax3 expression.
The multiple biochemical pathways affected by high glucose
are complex (Fig. 6). For example, we have shown that the
diacylglycerol (DAG)/protein kinase C (PKC) pathway is ac-
tivated in embryos of diabetic or hyperglycemic mice (26),
which could contribute to oxidative stress by activation of
NADPH oxidase activity (29), and that stimulation of the
hexosamine flux pathway by hyperglycemia causes oxidative
stress and inhibits Pax3 expression through depletion of GSH
(28). These effects may actually be secondary to hypoxia-
induced superoxide production. Du et al. (16) have shown that
increased mitochondrial superoxide production inhibits glyc-
eraldehyde-3-PO4 dehydrogenase (GAPDH) activity, which
causes glycolytic intermediates to accumulate. The glycolytic
intermediates, glyceraldehyde-3-PO4 and fructose-6-PO4, stimu-
late synthesis of DAG and glucosamine-6-PO4, respectively (5,
16). In support of this model in diabetic pregnancy, inhibition
of GAPDH has been observed in rat embryos exposed to a
hyperglycemic environment (53). Thus the data presented here,
in which maternal hyperglycemia of 19 mmol/l, or 12% O2,
caused the same quantitative changes in markers of oxidant
status, Pax3 expression, and NTD, suggest that many of the
effects of hyperglycemia result from O2 depletion-induced
oxidative stress. Further research will be necessary to deter-
mine whether the activation of PKC and hexosamine pathways
is solely the result of increased mitochondrial superoxide
production and inhibition of GAPDH activity and exactly how
oxidative stress leads to inhibition of Pax3 expression.
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